Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands

Michelle Maria Aleida Kip, M. Bosch, K. Fischer, R.Y.J. Tamminga, I. Lepage-Nefkens

    Research output: Contribution to conferencePaper

    Original languageEnglish
    Publication statusPublished - 8 Nov 2014
    EventISPOR 17th Annual European Congress 2014: New challenges for improving European health care - Amsterdam RAI, Amsterdam, Netherlands
    Duration: 8 Nov 201412 Nov 2014

    Conference

    ConferenceISPOR 17th Annual European Congress 2014
    Abbreviated titleISPOR
    CountryNetherlands
    CityAmsterdam
    Period8/11/1412/11/14

    Keywords

    • METIS-306280
    • IR-92434

    Cite this

    Kip, M. M. A., Bosch, M., Fischer, K., Tamminga, R. Y. J., & Lepage-Nefkens, I. (2014). Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands. Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands.
    Kip, Michelle Maria Aleida ; Bosch, M. ; Fischer, K. ; Tamminga, R.Y.J. ; Lepage-Nefkens, I. / Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands. Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands.
    @conference{30b2fe2bb17c48868fc40a14ef774757,
    title = "Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands",
    keywords = "METIS-306280, IR-92434",
    author = "Kip, {Michelle Maria Aleida} and M. Bosch and K. Fischer and R.Y.J. Tamminga and I. Lepage-Nefkens",
    year = "2014",
    month = "11",
    day = "8",
    language = "English",
    note = "ISPOR 17th Annual European Congress 2014 : New challenges for improving European health care, ISPOR ; Conference date: 08-11-2014 Through 12-11-2014",

    }

    Kip, MMA, Bosch, M, Fischer, K, Tamminga, RYJ & Lepage-Nefkens, I 2014, 'Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands' Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands, 8/11/14 - 12/11/14, .

    Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands. / Kip, Michelle Maria Aleida; Bosch, M.; Fischer, K.; Tamminga, R.Y.J.; Lepage-Nefkens, I.

    2014. Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands.

    Research output: Contribution to conferencePaper

    TY - CONF

    T1 - Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands

    AU - Kip, Michelle Maria Aleida

    AU - Bosch, M.

    AU - Fischer, K.

    AU - Tamminga, R.Y.J.

    AU - Lepage-Nefkens, I.

    PY - 2014/11/8

    Y1 - 2014/11/8

    KW - METIS-306280

    KW - IR-92434

    M3 - Paper

    ER -

    Kip MMA, Bosch M, Fischer K, Tamminga RYJ, Lepage-Nefkens I. Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands. 2014. Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands.